Advertisement

Topics

FDA Grants Genentech’s Hemophilia Drug Breakthrough Therapy Designation Despite Reports of Patien...

20:00 EDT 16 Apr 2018 | BioSpace

The U.S. Food and Drug Administration (FDA) granted Genentech, a Roche company, Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) for hemophilia A without factor VIII inhibitors.

Original Article: FDA Grants Genentech’s Hemophilia Drug Breakthrough Therapy Designation Despite Reports of Patien...

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Genentech’s Hemophilia Drug Breakthrough Therapy Designation Despite Reports of Patien..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...